SCHEMBL344191

SCHEMBL344191

CC(C)(C)OC(=O)N1CCOCC1

nearest known ligand 0.96

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.96
USP2 O75604 1/20 0.96
RECQL P46063 2/20 0.73
TSHR P16473 1/20 0.55
RAB9A P51151 1/20 0.50
HPGD P15428 1/20 0.49
LMNA P02545 1/20 0.47
POLB P06746 1/20 0.47
GPR119 Q8TDV5 2/20 0.47
EPHX1 P07099 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
TP53 P04637 1/20 0.46
CTSD P07339 2/20 0.46
CTSL P07711 2/20 0.46
CTSB P07858 2/20 0.46
CTSS P25774 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20448044 0.98 SMN1; SMN2 (1.00) SMN1; SMN2USP2RECQLTSHRRAB9A
Acetic Acid SCHEMBL29118271 0.94 SMN1; SMN2 (0.86) SMN1; SMN2USP2RECQLTSHRRAB9A
SCHEMBL2920417 0.93 SMN1; SMN2 (0.83) SMN1; SMN2USP2RECQLTSHRRAB9A
SCHEMBL392980 0.93 SMN1; SMN2 (0.83) SMN1; SMN2USP2RECQLTSHRPOLB
SCHEMBL18084793 0.91 SMN1; SMN2 (0.80) SMN1; SMN2USP2RECQLTSHRRAB9A
SCHEMBL28204425 0.91 SMN1; SMN2 (0.80) SMN1; SMN2USP2RECQLTSHRRAB9A
Formic Acid Methyl Ester SCHEMBL29022264 0.89 SMN1; SMN2 (0.77) SMN1; SMN2USP2RECQLTSHRRAB9A
SCHEMBL779445 0.88 SMN1; SMN2 (0.76) SMN1; SMN2USP2RECQLTSHRRAB9A
SCHEMBL12629406 0.88 USP2 (0.76) SMN1; SMN2USP2RECQLTSHRHPGD
SCHEMBL3086430 0.88 USP2 (0.75) SMN1; SMN2USP2RECQLTSHRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 433 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122011388-A Polyimide precursor, preparation method thereof and polyimide precursor composition 深圳先进电子材料国际创新研究院 2026-05-12 CN claimed
CN-110785420-B Oxazepin derivatives as inhibitors of PI 3-kinase activity 葛兰素史克知识产权开发有限公司 2022-04-26 CN claimed
CN-106170489-B New Pyrazolopyrimidine derivative and its purposes as MALT1 inhibitor 诺华股份有限公司 2019-05-03 CN claimed
CN-122011388-A Polyimide precursor, preparation method thereof and polyimide precursor composition 深圳先进电子材料国际创新研究院 2026-05-12 CN disclosed
US-20260027090-A1 Methods of Inhibiting Osteoclastogenesis and Osteoclast Activity VTV THERAPEUTICS LLC (US) 2026-01-29 US disclosed
US-20250281424-A1 SMALL MOLECULE ANTAGONISTS OF PF4 ZHOU YUHANG (US) 2025-09-11 US disclosed
US-20250206724-A1 SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2025-06-26 US disclosed
CN-120025326-A Heterocyclic compound of bifunctional chimera for targeting and degrading androgen receptor and application thereof 广东东阳光药业股份有限公司 2025-05-23 CN disclosed
CN-119894896-A Inhibitors of green peroxidase 阿斯利康(瑞典)有限公司 2025-04-25 CN disclosed
WO-2025067111-A1 MENIN-MLL INTERACTION INHIBITOR AND PREPARATION METHOD THEREFOR, AND APPLICATION 苏州必扬医药科技有限公司 2025-04-03 WO disclosed
CN-119604287-A Heterocyclic PAD4 inhibitors 细胞基因公司 2025-03-11 CN disclosed
US-20060205697-A1 Novel betulin derivatives, preparation thereof and use thereof MYREXIS, INC. 2006-09-14 US disclosed
CN-1784396-A p38 inhibitors and methods of their use ARRAY BIOPHARMA INC (US) 2006-06-07 CN disclosed
WO-2006053255-A2 NOVEL BETULIN DERIVATIVES, PREPARATION THEREOF AND USE THEREOF PANACOS PHARMACEUTICALS, INC. (US) 2006-05-18 WO disclosed
EP-1652866-A1 ACRYLIC POLYMERS AND RADIATION-SENSITIVE RESIN COMPOSITIONS JSR Corporation (JP) 2006-05-03 EP disclosed
WO-2006034093-A2 3- (2-ACYLAMINO-1-HYDROXYETHYL)- MORPHOLINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS ELLI LILLY AND COMPANY (US) 2006-03-30 WO disclosed
CN-1265661-A N-acylamino acid amide compounds and intermediates for preparation thereof UBE INDUSTRIES (JP) 2000-09-06 CN disclosed
CN-1107151-A Coumarin derivatives, their preparation and their use in the treatment of cerebrovascular disorders SANKYO CO (JP) 1995-08-23 CN disclosed
CN-1028527-C Process for preparing coumarin derivatives SANKYO CO (JP) 1995-05-24 CN disclosed
CN-1049662-A Coumarin derivative, preparation thereof and application thereof in treating cerebrovascular disorder SANKYO CO (JP) 1991-03-06 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205697-A1 Novel betulin derivatives, preparation thereof and use thereof BET1, PGGT1B, TMPO SMN1; SMN2 4756/4885USP2 4851/4885RECQL 3614/4885
US-20250206724-A1 SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS CDK1, CDK11A, CDK3 SMN1; SMN2 2939/4885USP2 2268/4885RECQL 1594/4885
US-20260027090-A1 Methods of Inhibiting Osteoclastogenesis and Osteoclast Activity CSF1R, CD209, NFATC1 SMN1; SMN2 4666/4885USP2 2679/4885RECQL 4876/4885
US-20250281424-A1 SMALL MOLECULE ANTAGONISTS OF PF4 PF4, F12, F2 SMN1; SMN2 4700/4885USP2 4654/4885RECQL 638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.